
    
      Eligible patients will receive apatinib treatment(500mg qd p.o. q28d) until until disease
      progression or intolerable toxicity or patients withdrawal of consent after 4 cycles of DC
      first-line chemotherapy or only DC first-line chemotherapy.
    
  